Search

Craig Mullen Phones & Addresses

  • Bethesda, MD
  • Nantucket, MA
  • Missoula, MT
  • Upper Marlboro, MD
  • West Jordan, UT
  • Bozeman, MT
  • PO Box 49, Siasconset, MA 02564 (207) 752-1391

Work

Position: Food Preparation and Serving Related Occupations

Education

Degree: Associate degree or higher

Emails

Professional Records

Medicine Doctors

Craig Mullen Photo 1

Craig A. Mullen

View page
Specialties:
Pediatric Hematology-Oncology
Work:
University Rochester Medical Center Pediatric Hematology Oncology
601 Elmwood Ave, Rochester, NY 14642
(585) 275-2981 (phone), (585) 273-1039 (fax)
Education:
Medical School
University of Chicago Pritzker School of Medicine
Graduated: 1986
Procedures:
Bone Marrow Biopsy
Chemotherapy
Conditions:
Anemia
Hemolytic Anemia
Hodgkin's Lymphoma
Leukemia
Sickle-Cell Disease
Languages:
English
Description:
Dr. Mullen graduated from the University of Chicago Pritzker School of Medicine in 1986. He works in Rochester, NY and specializes in Pediatric Hematology-Oncology. Dr. Mullen is affiliated with Highland Hospital Of Rochester and Strong Memorial Hospital.

License Records

Craig Mullen

License #:
RS136412A - Expired
Category:
Real Estate Commission
Type:
Real Estate Salesperson-Standard

Resumes

Resumes

Craig Mullen Photo 2

Director Of Operations

View page
Location:
Key Largo, FL
Industry:
Maritime
Work:
Hlp-Capital 2004 - 2011
Managing Partner

Sconset Ventures 1997 - 2011
Managing Partner

Deep Blue Surveys 1997 - 2011
Director of Operations

Aurora Trust Foundation 1997 - 2011
Founder and Managing Director
Education:
Woodruff High School In Peoria Il
Western Illinois University
Western Illinois University
Bachelors, Bachelor of Science, Microbiology
Skills:
Hydrographic Survey
Offshore Drilling
Maritime
Coastal
Surveying
Side Scan Sonar
Diving
Management
Navigation
Underwater
Scuba Diving
Hydrography
Sailing
Maritime Security
Ports
Environmental Awareness
Maritime Operations
Hydraulics
Project Management
Pipelines
Engineering
Energy
Risk Assessment
Rov
Safety Management Systems
Inspection
Subsea Engineering
Navy
Environmental Monitoring
Dredging
Gps
Craig Mullen Photo 3

President

View page
Location:
Siasconset, MA
Industry:
Venture Capital & Private Equity
Work:
Sconset Ventures
President
Craig Mullen Photo 4

Craig Mullen

View page
Craig Mullen Photo 5

Craig Mullen

View page
Craig Mullen Photo 6

Craig Mullen

View page
Craig Mullen Photo 7

Craig Mullen

View page
Craig Mullen Photo 8

Craig Mullen

View page
Craig Mullen Photo 9

Student Of Philosophy At Salisbury University

View page
Location:
Salisbury, Maryland
Industry:
Research
Education:
Salisbury University 2005 - 2013

Publications

Us Patents

Cytosine Deaminase Negative Selection System For Gene Transfer Techniques And Therapies

View page
US Patent:
53588665, Oct 25, 1994
Filed:
Jul 3, 1991
Appl. No.:
7/725076
Inventors:
Craig A. Mullen - Bethesda MD
R. Michael Blaese - Rockville MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12P 2106
C12N 500
C12N 978
C07H 2104
US Classification:
4352402
Abstract:
The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by mammalian cells. The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolite 5-fluorouracil from 5-fluorocytosine.

Cytosine Deaminase Negative Selection System For Gene Transfer Techniques And Therapies

View page
US Patent:
56248300, Apr 29, 1997
Filed:
Jul 7, 1994
Appl. No.:
8/271874
Inventors:
Craig A. Mullen - Bethesda MD
R. Michael Blaese - Rockville MD
Assignee:
The United States of America as represented by the Department of Health
and Human Services - Washington DC
International Classification:
C12N 510
C12N 978
C12P 2102
US Classification:
4351723
Abstract:
The present invention relates to a system comprising a modified bacterial gene for cytosine deaminase that has been engineered into a eukaryotic expression vector and the expression of the gene by mammalian cells. The present invention further relates to methods, gene therapies and vaccines that employ the negative selectable marker, cytosine deaminase, which has the ability to produce a toxic antimetabolic 5-fluorouracil from 5-fluorocytosine.
Craig Thomas Mullen from Bethesda, MD, age ~81 Get Report